retatrutide phase 3 2025 triple agonist glp-1 gip glucagon is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Retatrutide (LY3437943): Mechanism of Action

Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome

El Mously S, Abdel Ghaffar H, Magdy R, Hamza S, Mansour M

L-carnitine appears in heart-health discussions, but research is ongoing and it should not be treated as a standalone answer

4.4 Mechanistic exploration of repurposed anti-diabetic drugs Preclinical data reporting the neuroprotective effects of drugs such as GLP-1 receptor agonists (e.g., Liraglutide) and SGLT2 inhibitors raise the possibility that their benefits extend beyond glycemic control to potentially encompass the inhibition of ferroptosis (Xie et al., 2023)

Possible Side Effects and What to Watch For The most common side effects are nausea, vomiting, diarrhoea, and constipation, especially during dose escalation

doi: 10.3390/genes9050249 73 ShintaniT.SakoguchiH.YoshiharaA.IzumoriK.SatoM